Prothena Gestione

Gestione criteri di controllo 2/4

Prothena Il CEO è Gene Kinney, nominato in Sep2016, e ha un mandato di 8.17 anni. la retribuzione annua totale è $ 7.04M, composta da 9% di stipendio e 91% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.024% delle azioni della società, per un valore di $ 192.88K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.7 anni e 5.1 anni.

Informazioni chiave

Gene Kinney

Amministratore delegato

US$7.0m

Compenso totale

Percentuale dello stipendio del CEO	9.0%
Mandato del CEO	8.2yrs
Proprietà del CEO	0.02%
Durata media del management	7.7yrs
Durata media del Consiglio di amministrazione	5.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gene Kinney rispetto agli utili di Prothena?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$132m
Jun 30 2024	n/a	n/a	-US$51m
Mar 31 2024	n/a	n/a	-US$172m
Dec 31 2023	US$7m	US$631k	-US$147m
Sep 30 2023	n/a	n/a	-US$73m
Jun 30 2023	n/a	n/a	-US$141m
Mar 31 2023	n/a	n/a	-US$128m
Dec 31 2022	US$7m	US$601k	-US$117m
Sep 30 2022	n/a	n/a	-US$156m
Jun 30 2022	n/a	n/a	-US$1m
Mar 31 2022	n/a	n/a	US$67m
Dec 31 2021	US$5m	US$573k	US$67m
Sep 30 2021	n/a	n/a	US$69m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$124m
Dec 31 2020	US$3m	US$554k	-US$111m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$91m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$3m	US$538k	-US$78m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$84m
Mar 31 2019	n/a	n/a	-US$128m
Dec 31 2018	US$11m	US$525k	-US$156m
Sep 30 2018	n/a	n/a	-US$181m
Jun 30 2018	n/a	n/a	-US$209m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$5m	US$521k	-US$153m

Compensazione vs Mercato: La retribuzione totale di Gene ($USD 7.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 1.45M ).

Compensazione vs guadagni: La retribuzione di Gene è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Gene Kinney (55 yo)

8.2yrs

Mandato

US$7,043,826

Compensazione

Dr. Gene G. Kinney, Ph D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gene Kinney	President	8.2yrs	US$7.04m	0.024% $ 192.9k
Tran Nguyen	CFO & Chief Strategy Officer	11.7yrs	US$2.70m	0.0060% $ 48.3k
Brandon Smith	Chief Operating Officer	3.1yrs	US$2.63m	0% $ 0
Carol Karp	Chief Regulatory Officer	7.9yrs	US$2.57m	0% $ 0
Karin Walker	Chief Accounting Officer & Controller	11.5yrs	Nessun dato	Nessun dato
Wagner Zago	Chief Scientific Officer	7.4yrs	US$3.34m	Nessun dato
Mark Johnson	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Michael Malecek	Chief Legal Officer	no data	US$1.18m	Nessun dato
David Ford	Chief People Officer	less than a year	Nessun dato	Nessun dato
Chad Swanson	Chief Development Officer	less than a year	Nessun dato	Nessun dato
Yvonne Tchrakian	Company Secretary	no data	Nessun dato	Nessun dato

7.7yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 0Y3M è esperto e expertise (durata media dell'incarico 7.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gene Kinney	President	8.2yrs	US$7.04m	0.024% $ 192.9k
Helen Kim	Independent Director	2.3yrs	US$896.63k	0% $ 0
Richard Collier	Independent Director	11.9yrs	US$912.48k	0.0023% $ 18.4k
Daniel Welch	Independent Chairman	less than a year	Nessun dato	Nessun dato
Lars Ekman	Independent Chair Emeritus	less than a year	US$923.48k	0.00045% $ 3.7k
Shane Cooke	Independent Director	11.9yrs	US$917.26k	0% $ 0
Dennis Selkoe	Independent Director	11.3yrs	US$901.73k	0.0078% $ 63.5k
Paula Cobb	Independent Director	5.3yrs	US$908.48k	0% $ 0
Oleg Nodelman	Independent Director	4.9yrs	Nessun dato	Nessun dato
William Dunn	Independent Director	1.5yrs	US$1.70m	Nessun dato

5.1yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0Y3M sono considerati esperti (durata media dell'incarico 5.1 anni).

Prothena Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Prothena Corporation plc Announces Appointment of Chad Swanson as Chief Development Officer

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Prothena Corporation plc Announces Board Changes

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Recent updates

Third quarter 2024 earnings released: US$1.10 loss per share (vs US$0.41 profit in 3Q 2023)

Prothena Corporation plc to Report Q3, 2024 Results on Nov 12, 2024

Prothena Corporation plc Announces Appointment of Chad Swanson as Chief Development Officer

Second quarter 2024 earnings released: EPS: US$1.24 (vs US$1.03 loss in 2Q 2023)

Prothena Corporation plc Revises Financial Guidance for the Full Year of 2024

Prothena Corporation plc to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$1.35 loss per share (vs US$0.89 loss in 1Q 2023)

Prothena Corporation plc to Report Q1, 2024 Results on May 08, 2024

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc has filed a Follow-on Equity Offering in the amount of $250 million.

Prothena Corporation plc Announces Board Changes

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Prothena Corporation plc to Report Q4, 2023 Results on Feb 15, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.97 loss in 3Q 2022)

Prothena Corporation plc to Report Q3, 2023 Results on Nov 02, 2023

Prothena Reportedly Prepares for Potential Sale

Prothena Reportedly Prepares for Potential Sale

Second quarter 2023 earnings released: US$1.03 loss per share (vs US$0.88 loss in 2Q 2022)

Prothena Corporation plc to Report Q2, 2023 Results on Aug 03, 2023

Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International Conference®? 2023

Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.78 loss in 1Q 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.47 loss per share (vs US$1.51 profit in FY 2021)

Prothena Corporation plc to Report Q4, 2022 Results on Feb 23, 2023

Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005

Prothena Corporation plc Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Third quarter 2022 earnings released: US$0.97 loss per share (vs US$2.39 profit in 3Q 2021)

Prothena Corporation plc to Report Q3, 2022 Results on Nov 03, 2022

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Second quarter 2022 earnings released: US$0.88 loss per share (vs US$0.62 profit in 2Q 2021)

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q2, 2022 Results on Aug 08, 2022

Prothena Corporation plc(NasdaqGS:PRTA) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Prothena Corporation plc Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

Prothena Corporation plc, Annual General Meeting, May 17, 2022

Prothena Corporation plc Announces U.S. Food and Drug Administration Clearance of IND for PRX012, A Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q4, 2021 Results on Feb 17, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$2.39 (vs US$0.77 loss in 3Q 2020)

Forecast to breakeven in 2021

Second quarter 2021 earnings released: EPS US$0.62 (vs US$0.66 loss in 2Q 2020)

Forecast to breakeven in 2021

Forecast to breakeven in 2021

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.59 loss in 1Q 2020)

Prothena Corporation plc Provides Earnings Guidance for the Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Prothena Corporation plc Announces Promising New Preclinical and Clinical Data from Its Neurodegenerative Programs Selected for Oral Presentations At AD/PD 2021

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Revenue beats expectations

Prothena Corporation plc to Report Q4, 2020 Results on Feb 11, 2021

Prothena Corporation plc Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media